Friday, May 15, 2009

Free Report from PWC: "PHARMA 2020 - WHICH PATH WILL YOU TAKE?"

Most Big Pharma companies have traditionally done everything from research and development (R&D) through to commercialization themselves. However, by 2020 this model will no longer work for many organizations. If they are to prosper, they will need to improve their R&D productivity, reduce their costs, tap the potential of the emerging economies and switch from selling medicines to managing outcomes. These activities few companies, if any, can accomplish on their own.

The Report, which is divided into 4 parts and provided for FREE by Price Waterhouse Coopers, explores the some key issues, provides valuable insights, and lays out a roadmap that can help pharma make the transition to a new business model successfully.

PART 4: Pharma 2020: Challenging business models - Which path will you take? - April 2009

Fourth in the Pharma 2020 series, this report explains why Pharma's fully integrated business models may not be the best option for the pharma industry in 2020 and why more creative collaboration models may be more attractive. The paper also evaluates the advantages and disadvantages of the alternative business models and how each stands up against the challenges facing the industry.

PART 3: Pharma 2020: Marketing the future - Which path will you take? - February 2009

Third in the PwC Pharma 2020 series, discusses how the industry is no longer being rewarded for incremental innovation, me-too products and selling the most pills. Companies need to add value to patients, and offer a package of products and health services that the market is willing to pay a premium for.

PART 2: Pharma 2020: Virtual R&D - Which path will you take? - June 2008

Second in the series explores opportunities to improve the R&D process. This paper proposes that new technologies will enable the adoption of virtual R & D; and by operating in a more connected world, industry, in collaboration with researches, governments, healthcare payers and providers, can address the changing needs of society more effectively.

PART 1: Pharma 2020: The vision - Which path will you take? - June 2007

First in the series highlights a number of issues that will have a major bearing on the industry over the next 11 years. The publication outlines the changes we believe will best help pharmaceutical companies realise the potential the future holds to enhance the value they provide to shareholders and society alike.

Click here to go to the PWC page where you can download the report (reg. required).

buzz this

blog comments powered by Disqus